Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Proactive Investors

11:21 EDT 18th June 2018 | BioPortfolio

Here are the most relevant search results for "Proactive Investors" found in our extensive news archives from over 250 global news sources.

More Information about Proactive Investors on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Proactive Investors for you to read. Along with our medical data and news we also list Proactive Investors Clinical Trials, which are updated daily. BioPortfolio also has a large database of Proactive Investors Companies for you to search.

Showing News Articles 1–25 of 1,100+ from Proactive Investors

Monday 18th June 2018

Ocado downgraded by Bank of America Merrill Lynch as it enters execution phase of Kroger deal

Analysts said that the next few years for the FTSE 250-online grocer would be about “delivering results and validating the economics rather than signing new partnerships"

Bidding war brewing for GSK’s Indian Horlicks division, with Coca-Cola, Nestle and Kraft all reportedly interested

Horlicks might not be big business in the UK anymore, but it is India, where hundreds of thousands of kids drink it every day for breakfast

hVIVO readies flu vaccine for final stage trial as it sails through phase II

“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain."

Motif Bio completes rolling submission of NDA for new antibiotic Iclaprim

Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB), tells Proactive's Andrew Scott they've completed a rolling submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for their new antibiotic Iclaprim. Lumsden says upon acceptance of the filing of the NDA by the FDA, Iclaprim will receive priority review - a review period of six months instead of the st...

DS Smith profits bolstered by acquisitions and recovering paper prices

DS Smith said it is confident on the outlook for the year ahead with volume growth momentum seen continuing

Indivior wins temporary legal respite as competitor is prevented by court from launching cheap copycat product

The restraining order, handed down by the US District Court for the District of New Jersey, will remain in place pending a hearing on the preliminary injunction motion filed by Indivior last Friday

Geron shares pop in pre-market trade on optimistic clinical trial results for its drug therapy imetelstat

Its drug therapy imetelstat is used to treat lower-risk myelodysplastic syndrome, a type of blood cancer

OptiBiotix strikes SlimBiome manufacturing and supply deal with Morley Foods

Morleys supplies ingredients to major retailers and several consumer food brands and has spent the last six months developing a range of muesli products which contain SlimBiome

Sunday 17th June 2018

Zelda Therapeutics ready to test 'entourage effect' hypothesis in cancer research

Zelda Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) executive chairman Harry Karelis tells Proactive Investors the medical cannabis researcher's latest news. Initial results from a paediatric brain cancer study being conducted with the Telethon Kids Institute in Perth have validated that two chemicals naturally occurring in the cannabis plant, THC and CBD, each have some anti-cancer effects. Zelda ...

Friday 15th June 2018

Daily CryptoCann Report: Imogen Heap funds crypto project; Canadian cannabis companies raise US$671mln in June

Cannabis! Crptocurrencies! The Daily CryptoCann Report is where we take some time to focus on both areas. 

Daily CryptoCann Report: Imogen Heap funds crypto project with Harry Potter money; Canadian cannabis companies raise US$671mln in June

The Grammy-award winner is working on a blockchain project for musicians

Large-cap biotech companies seem poised to outperform in 2Q, says Oppenheimer analyst

'We remain cautiously bullish on the sector, albeit with a stock-picking approach,' writes Hartaj Singh

Oppenheimer debunks ‘competitor myths’ surrounding Portola Pharmaceuticals’ AndexXa bleeding antidote

The analysts thumped the table for AndexXa forecasting peak sales of US$1.25bn in 2029

Elite Pharmaceuticals reports sharp drop in revenue in fiscal 2018 due to sluggish sales of methadone

Sales of generic methadone and naltrexone, a drug used to treat alcoholism, slowed in fiscal 2018

Trading in AMAG Pharmaceuticals resumes; stock slips on FDA's recommended changes to drug safety label

The proposed changes to iron deficiency anemia drug Feraheme go beyond what the company proposed in June 2014

Advisory committee tells US regulators to reject BTG’s Elevair emphysema treatment

The panel wasn’t convinced that Elevair would have any effect on those taking it, or that the possible benefits outweighed the risks

Silence Therapeutics presentation will say lead drug is a "promising candidate" for the treatment of iron overload and anaemia

Researchers have been assessing its potential use in Beta-Thalassemia - a blood disorder which reduces the production of haemoglobin

Silence Therapeutics presentation will say lead drug is a "promising candidate" for the treatment of iron overload and anaemia

Researchers have been assessing its potential use in Beta-Thalassemia - a blood disorder reduces the production of haemoglobin

Thursday 14th June 2018

ValiRx surges as it continues “advanced conversations” with possible partners for lung cancer drug

ValiRx released the positive results of a phase II trial of its lead drug earlier this year and it is now looking for a partner to help take VAL401 through a phase III study and into the market

Avacta Group Plc focused on securing third-party deals for both sides of the business

Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT), talks Proactive's Andrew Scott through the latest developments across the business. Looking ahead, Smith says: ''The priorities for us without doubt are third party deals  on both sides - be they licensing deals, supply deals etc on the reagents and diagnostics side and we've got a really full pipeline of high quality partner...

Deliveroo vs Just Eat: is the market big enough to accommodate both?

The two food delivery giants are clearly in a turf war

Daily CryptoCann Report: William Shatner boldly goes to Bitcoin; Kush Bottles raises US$36mln

Western Union says no to adding a cryptocurrency transfer service

Liberum ups target for Majestic Wine amid growing exposure and customer growth spending

The City broker said the group’s results for the 2018 financial year had confirmed progress had been made as well as being a “significant” surprise

Genprex making strides to take cancer-fighting drug Oncoprex to FDA approval

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive Investors the bio-pharmaceutical company is making great strides toward developing the company's non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex. Varner says Oncoprox is in Phase 2 of clinical trials, and next steps are to meet with the FDA about best pathways forward to an approval. The company recently went public...

Motif Bio completes FDA submission for Iclaprim antibiotic

The AIM-listed bio-pharma company said Iclaprim had received Qualified Infectious Disease Product designation from the FDA together with Fast Track Designation


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks